Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Community pharmacists as behavioral health extenders: an effectiveness-implementation hybrid type II feasibility evaluation.

BMC health services research·2026
Same author

Screening and referral programs for diabetes and cardiovascular disease: Can community pharmacists bridge the care gap?

Exploratory research in clinical and social pharmacy·2024
Same author

Community Pharmacy Recruitment for Practice-Based Research: Challenges and Lessons Learned.

Pharmacy (Basel, Switzerland)·2023
Same author

Microbiome: Detecting diversity.

Nature·2017
Same author

Sex differences: Luck of the chromosomes.

Nature·2014
Same author

Drug development: a complicated path.

Nature·2014
Same journal

Retraction Note: NSD2 targeting reverses plasticity and drug resistance in prostate cancer.

Nature·2026
Same journal

Enhanced B cell priming induces broadly neutralizing HIV-1 apex antibodies.

Nature·2026
Same journal

Vaccination elicits HIV broadly neutralizing antibodies in primates.

Nature·2026
Same journal

Child online safety needs more than social-media bans.

Nature·2026
Same journal

Ebola preparedness must start with ecosystems and before humans show symptoms.

Nature·2026
Same journal

AI tools can speed up thinking, but evidence still comes from the lab bench.

Nature·2026
See all related articles

Related Experiment Video

Updated: May 23, 2026

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Progressive multiple sclerosis: The treatment gap

Courtney Humphries

    Nature
    |April 18, 2012
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
    11:35

    The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

    Published on: June 30, 2014

    Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
    08:51

    Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

    Published on: February 19, 2021

    Related Experiment Videos

    Last Updated: May 23, 2026

    Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
    08:11

    Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

    Published on: November 14, 2016

    The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
    11:35

    The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

    Published on: June 30, 2014

    Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
    08:51

    Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

    Published on: February 19, 2021